Literature DB >> 8505857

Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis.

J Homolka1, J Müller-Quernheim.   

Abstract

Alveolitis of sarcoidosis is characterized by activated alveolar macrophages (AMs) and T cells. The mediators interleukin-1 (IL-1) and interleukin 6 (IL-6) released by AMs represent essential factors for the progression of the T cells in the cell cycle. The role of IL-1 in pulmonary sarcoidosis has previously been studied; however, the relevance of other mediators (i.e. IL-6) has not yet been evaluated. We measured the spontaneous and lipopolysaccharide (LPS)-induced release of IL-6 and tumor necrosis factor alpha (TNF alpha) by bronchoalveolar lavage cells (BAL) and peripheral blood mononuclear cells (PBMNC) in 6 control subjects (group A) and in 15 patients with sarcoidosis, 10 with active (group B), 5 with inactive disease (group C). IL-6 as well as TNF alpha were spontaneously released by BAL cells of the active group in significantly greater amounts compared to both other groups; IL-6: A, 165.5 pg/ml/24 hr/10(6) cells (range, 0-604), B, 946 (0-2467), C, 16.6 (0-83); TNF alpha: A, 162 pg/ml/24 hr/10(6) cells (0-523), B, 803 (100-17352), C, 100 (0-379). In all groups autologous PBMNC proved to be quiescent, releasing only baseline levels of the cytokines tested. After stimulation with LPS all these cells released great quantities of IL-6 and TNF alpha. In active disease a positive correlation between IL-6 and TNF alpha release was observed (r = 0.77, p < 0.02). The present study documents that in active sarcoidosis the spontaneous release of IL-6 by BAL cells parallels the spontaneous release of TNF alpha. IL-6 is capable of initiating the proliferation and activation of T cells in the lung.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8505857     DOI: 10.1007/BF00183946

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  43 in total

Review 1.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).

Authors:  S Akira; T Hirano; T Taga; T Kishimoto
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

2.  Multiple actions of interleukin 6 within a cytokine network.

Authors:  G G Wong; S C Clark
Journal:  Immunol Today       Date:  1988-05

3.  High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis.

Authors:  P M Suter; S Suter; E Girardin; P Roux-Lombard; G E Grau; J M Dayer
Journal:  Am Rev Respir Dis       Date:  1992-05

4.  Distinct roles of IL-1 and IL-6 in human T cell activation.

Authors:  F A Houssiau; P G Coulie; J Van Snick
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

5.  Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage.

Authors:  T W Marcy; W W Merrill; J A Rankin; H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1987-06

6.  The immunoperoxidase slide assay. A new method for the demonstration of surface antigens on bronchoalveolar lavage cells.

Authors:  U Costabel; K J Bross; H Matthys
Journal:  Bull Eur Physiopathol Respir       Date:  1985 Jul-Aug

7.  Human alveolar macrophage and blood monocyte interleukin-6 production.

Authors:  R M Kotloff; J Little; J A Elias
Journal:  Am J Respir Cell Mol Biol       Date:  1990-11       Impact factor: 6.914

8.  Two distinct factors are required for induction of T-cell growth.

Authors:  E L Larsson; N N Iscove; A Coutinho
Journal:  Nature       Date:  1980-02-14       Impact factor: 49.962

9.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity.

Authors:  G W Hunninghake; R G Crystal
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

10.  Role of interleukin 6 for differential responsiveness of naive and memory CD4+ T cells in CD2-mediated activation.

Authors:  Y Kasahara; T Miyawaki; K Kato; H Kanegane; A Yachie; T Yokoi; N Taniguchi
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

View more
  6 in total

1.  Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis.

Authors:  I Bäumer; G Zissel; M Schlaak; J Müller-Quernheim
Journal:  Lung       Date:  1997       Impact factor: 2.584

2.  Increased interleukin-13 expression in patients with sarcoidosis.

Authors:  H-P Hauber; D Gholami; A Meyer; A Pforte
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

3.  Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis.

Authors:  M I Gabrilovich; J Walrath; J van Lunteren; D Nethery; M Seifu; J A Kern; C V Harding; L Tuscano; H Lee; S D Williams; W Mackay; J F Tomashefski; R F Silver
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

4.  Evaluation of inflammatory cytokine secretion by human alveolar macrophages.

Authors:  J E Losa García; F M Rodríguez; M R Martín de Cabo; M J García Salgado; J P Losada; L G Villarón; A J López; J L Arellano
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

5.  Imbalance of pro- and anti-inflammatory cytokines in pulmonary sarcoidosis.

Authors:  J Müller-Quernheim
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

Review 6.  Adaptive Immunity in Pulmonary Sarcoidosis and Chronic Beryllium Disease.

Authors:  Sarah A Greaves; Shaikh M Atif; Andrew P Fontenot
Journal:  Front Immunol       Date:  2020-03-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.